TELA Bio adds William Plovanic to board of directors

TELA Bio Inc. (NASDAQ: TELA) announced the appointment of William Plovanic to its board of directors, according to a company press release. Plovanic currently serves as managing director of healthcare equity research at Canaccord Genuity.

Plovanic brings over 25 years of experience in capital markets, corporate strategy and medical device operations. From 2016 to 2021, he held executive positions including chief executive officer, president and chief financial officer at Obalon Therapeutics, a formerly publicly traded medical device company that was listed on Nasdaq under the ticker OBLN.

Earlier in his career, Plovanic held senior equity research positions at First Albany and Canaccord Genuity, focusing on medical technology and life sciences. He holds a Bachelor of Science in Finance from Bradley University and is a Chartered Financial Analyst charterholder.

"We are pleased to welcome Bill to our Board," said Antony Koblish, co-founder and chief executive officer of TELA Bio. "He bridges the worlds of Wall Street and operating leadership. His understanding of the capital markets—paired with direct experience running a publicly held med-tech company—will help to further strengthen our strategy and drive long-term shareholder value."

TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions. The Malvern, Pennsylvania-based company develops technologies designed to preserve and restore patient anatomy while minimizing exposure to permanent synthetic materials.

You May Also Be Interested In

• Sprinklr adds Microsoft's Jordi Ribas to its board of directors
• Mobix Labs agrees to acquire Special Project Delivery
• Check-Cap completes 1-for-7 reverse split ahead of MBody AI merger